Witzel I, et al. - Since, for many breast cancer patients, brain metastases (BMs) have an enormous impact on life expectancy and quality of life, researchers assessed treatment patterns and outcomes by examining the clinical data of 1,712 subjects diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions in Germany. According to the subtype, the prognosis of patients after the development of BMs differs significantly. It was noted that patients with HER2-positive tumors who received anti-HER2 treatment had longer median overall survival (OS) than those without. In triple-negative and HR-positive/HER2-negative patients, the outcome in this cohort is similarly poor.